Remes K, Tienhaara A, Pelliniemi T T
Department of Medicine, Turku University Central Hospital, Finland.
Br J Haematol. 1993 Jun;84(2):353-5. doi: 10.1111/j.1365-2141.1993.tb03082.x.
Serum beta-2-microglobulin (b2m) levels were studied in 10 patients treated with alpha interferon (IFN) for thrombocythaemia associated with chronic myeloproliferative diseases. In eight patients the IFN treatment decreased the blood platelet level to < 600 x 10(9)/l. Serum b2m levels rose significantly and dose-dependently immediately after the onset of treatment, by a median maximal increase of 72% with IFN 3 MU every other day, and 95% with 3 MU daily. The b2m rise caused by IFN abolishes the value of serum b2m in states where b2m is used as an indicator of disease activity.
对10例因慢性骨髓增殖性疾病伴血小板增多症而接受α干扰素（IFN）治疗的患者的血清β2-微球蛋白（b2m）水平进行了研究。8例患者经IFN治疗后血小板水平降至<600×10⁹/L。治疗开始后血清b2m水平立即显著且呈剂量依赖性升高，隔日使用3MU IFN时，b2m中位数最大增幅为72%，每日使用3MU IFN时为95%。IFN引起的b2m升高使b2m在作为疾病活动指标的状态下失去了血清b2m的价值。
